We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Enterprise Products (EPD) Q2 Earnings Top Estimates, Fall Y/Y
Read MoreHide Full Article
Enterprise Products Partners LP (EPD - Free Report) reported second-quarter 2020 adjusted earnings per limited partner unit of 47 cents, beating the Zacks Consensus Estimate by a penny. The bottom line, however, deteriorated from the year-ago quarter’s 55 cents per unit.
Revenues declined to $5,751 million from $8,276 million in the prior-year quarter. The top line also missed the consensus estimate of $6,962 million.
The better-than-expected earnings for the second quarter were supported by higher marine terminal volumes of NGL and increased margins from uncontracted storage capacity. The positives were partially offset by lower natural gas pipeline transportation volumes and decreased propylene production volumes
Enterprise Products Partners L.P. Price, Consensus and EPS Surprise
Gross operating income at NGL Pipelines & Services increased from $966.3 million in the year-ago quarter to $968.1 million on higher marine terminal volumes of NGL.
Natural Gas Pipelines and Services’ gross operating income decreased to $208.9 million from $301.8 million in the year-ago quarter. The downsize is owing to lower natural gas pipeline transportation volumes.
Crude Oil Pipelines & Services recorded gross operating income of $634.4 million, which increased from $513.2 million in the prior-year quarter owing to an increase in margins from uncontracted storage capacity.
Gross operating income at Petrochemical & Refined Products Services amounted to $191.5 million compared with $304.9 million a year ago. The underperformance was owing to the decrease in propylene production volumes.
DCF
Quarterly distribution improved 1.1% year over year to 44.50 cents per common unit or $1.78 per unit on an annualized basis.
Adjusted distributable cash flow was $1,577 million, down 8.4% year over year, and provided coverage of 1.6x. Notably, the partnership retained $597 million of distributable cash flow in the second quarter.
Financials
During the quarter, the partnership’s capital expenditure was $910 million.
As of Jun 30, 2020, its outstanding total debt principal was $29.9 billion. Enterprise Products’ consolidated liquidity amounted to $7.3 billion, which included unrestricted cash on hand and available borrowing capacity.
Outlook
The partnership foresees investment of roughly $2.5 billion to $3 billion for growth capital project for 2020. The partnership expects its sustaining capital expenditures for 2020 at $300 million. Moreover, Enterprise Products lowered growth capital investment projections for 2021 and 2022 to $2.3 billion and $1 billion, respectively, from the earlier projections.
NGL Energy Partners’ bottom line for second-quarter 2020 is expected to rise 92.7% year over year.
Cimarex Energy’ 2020 bottom-line estimates have moved up over the past 30 days.
EOG Resources’ 2020 bottom-line estimates have risen more than 200% over the past 30 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Enterprise Products (EPD) Q2 Earnings Top Estimates, Fall Y/Y
Enterprise Products Partners LP (EPD - Free Report) reported second-quarter 2020 adjusted earnings per limited partner unit of 47 cents, beating the Zacks Consensus Estimate by a penny. The bottom line, however, deteriorated from the year-ago quarter’s 55 cents per unit.
Revenues declined to $5,751 million from $8,276 million in the prior-year quarter. The top line also missed the consensus estimate of $6,962 million.
The better-than-expected earnings for the second quarter were supported by higher marine terminal volumes of NGL and increased margins from uncontracted storage capacity. The positives were partially offset by lower natural gas pipeline transportation volumes and decreased propylene production volumes
Enterprise Products Partners L.P. Price, Consensus and EPS Surprise
Enterprise Products Partners L.P. price-consensus-eps-surprise-chart | Enterprise Products Partners L.P. Quote
Segmental Performance
Gross operating income at NGL Pipelines & Services increased from $966.3 million in the year-ago quarter to $968.1 million on higher marine terminal volumes of NGL.
Natural Gas Pipelines and Services’ gross operating income decreased to $208.9 million from $301.8 million in the year-ago quarter. The downsize is owing to lower natural gas pipeline transportation volumes.
Crude Oil Pipelines & Services recorded gross operating income of $634.4 million, which increased from $513.2 million in the prior-year quarter owing to an increase in margins from uncontracted storage capacity.
Gross operating income at Petrochemical & Refined Products Services amounted to $191.5 million compared with $304.9 million a year ago. The underperformance was owing to the decrease in propylene production volumes.
DCF
Quarterly distribution improved 1.1% year over year to 44.50 cents per common unit or $1.78 per unit on an annualized basis.
Adjusted distributable cash flow was $1,577 million, down 8.4% year over year, and provided coverage of 1.6x. Notably, the partnership retained $597 million of distributable cash flow in the second quarter.
Financials
During the quarter, the partnership’s capital expenditure was $910 million.
As of Jun 30, 2020, its outstanding total debt principal was $29.9 billion. Enterprise Products’ consolidated liquidity amounted to $7.3 billion, which included unrestricted cash on hand and available borrowing capacity.
Outlook
The partnership foresees investment of roughly $2.5 billion to $3 billion for growth capital project for 2020. The partnership expects its sustaining capital expenditures for 2020 at $300 million. Moreover, Enterprise Products lowered growth capital investment projections for 2021 and 2022 to $2.3 billion and $1 billion, respectively, from the earlier projections.
Zacks Rank & Stocks to Consider
The partnership currently has a Zacks Rank #3 (Hold). Meanwhile, a few better-ranked players in the energy space include NGL Energy Partners LP (NGL - Free Report) , Cimarex Energy Co and EOG Resources, Inc. (EOG - Free Report) , each holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NGL Energy Partners’ bottom line for second-quarter 2020 is expected to rise 92.7% year over year.
Cimarex Energy’ 2020 bottom-line estimates have moved up over the past 30 days.
EOG Resources’ 2020 bottom-line estimates have risen more than 200% over the past 30 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>